SPCC shared on LinkedIn:
“Mark your calendars for this live webinar!
Date: 29 January 2025, 18:00 CET
Main topics:
∙ Review of the latest HR+ HER2- MBC data and description of the current and future treatment landscape
∙ Biomarker testing
∙ Biomarker vs non-biomarker driven treatment choices
∙ Optimal sequencing the current & future dependant on clinical characteristic (which?)
Discussant: Miguel Martin, ES
Experts: Patrick Neven, BE; Joyce O’Shaughnessy, US
Register now (free of charge).
This webinar is supported by an unrestricted educational grant from Eli Lilly.”
